March 2013

Editor's Page

Robert L. Avery, MD; and Allen C. Ho, MD;

Medical Volunteerism Abroad

Volunteer-based missions bring ophthalmologists the chance to offer their skills to those in need.

Rachel M. Renshaw, Editor-in-Chief

The Office of the Inspector General and You

George A. Williams, MD

Medical Device Regulation: A Review

Aron Shapiro; Maureen O'Connell; and Ryan Bouchard

Giant Retinal Tears: Size Does Matter

Pearls for managing a variety of surgical scenarios.

Manish Nagpal, MS, DO, FRCS(UK)

Natural Dyes for Chromovitrectomy

The efficacy of natural dyes in ocular surgery is under investigation.

Eduardo A. Novais, MD; Eduardo B. Rodrigues, MD; Magno Antonio Ferreira, MD; ane Chen, MD; André Maia, MD; Maurício Maia, MD; Emmerson Badaró, MD; Fernando M. Penha, MD; and Michel Eid Farah, MD

Strategies for Minimizing Radiation Maculopathy

Spenser J. Morton, BS; Priya Sharma, BS; and Carol L. Shields, MD

The Microplasmin for Pediatric Vitrectomy Study

Ocriplasmin has been evaluated in children in a phase 2 trial; results have not been announced.

Kimberly Drenser, MD, PhD

Update on FEVR: Diagnosis, Management, and Treatment

This lifelong disease requires prompt treatment and vigilant follow-up.

Franco M. Recchia, MD

Telemedicine for ROP: An Update

A remote screening program can leverage the efforts of a single skilled screener.

Darius M. Moshfeghi, MD

Papillophlebitis in a Young Girl Secondary to Homozygous Mutation of MTHFR C677T and A1298C Genotypes

Kiran Turaka, MD; Matthew C. Ziemianski, MD; and J. Shepard Bryan, MD

Update on Anti-VEGF Treatment for ROP

Some promising results with VEGF inhibition, but laser remains the standard of care.

Michael T. Trese, MD

Integrin Peptide Therapy for the Treatment of Vascular Eye Diseases

In addition to its effects in DME, this molecule can induce posterior vitreous detachment.

Baruch D. Kuppermann, MD, PhD

Anti-PDGF Combination Therapy in Neovascular Age-related Macular Degeneration: Results of a Phase 2b Study

Pravin U. Dugel, MD

Vitreomacular Adhesion: Pathology and Treatment

New pharmacologic treatment option is an alternative to surgery or watchful waiting.

David S. Boyer, MD

Innovations

5Q With Michael T. Trese, MD

Dr. Trese is a Clinical Professor of Ophthalmology at The Eye Research Institute of Oakland University, a Clinical Associate Professor at Wayne State University School of Medicine, and the Chief of Pediatric and Adult Vitreoretinal Surgery at William Beaumont Hospital in Michigan.

Universal Eye Screening in Healthy Neonates

Li Li-Hong, MD

Insurer Perspective on Telemedicine Screening for ROP

Arthur W. Allen Jr, MD

Insurer Perspective on Bevacizumab for ROP

Arthur W. Allen Jr, MD

Ocriplasmin in Practice